Department of Cancer Chemotherapy and Radiology, Tangshan Gongren Hospital, China.
Cancer Epidemiol. 2012 Apr;36(2):e111-5. doi: 10.1016/j.canep.2011.11.004. Epub 2011 Dec 23.
The complement system is an important immunosurveillance mechanism against tumors, and complement factor H (CFH) is a key regulator for activation of the complement system. Expression of complement factor H has been demonstrated in cell lines from several malignancies. In this study we examined the contribution of the single-nucleotide polymorphism (SNP) Try402His (Y402H) (rs1061170) in the CFH gene to the risk of lung cancer in a case-control study with 1000 cases and 1000 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed by logistic regression. The frequencies for CFH Y402H genotypes among the cases were statistically significantly different from those among controls (χ(2)=8.66, P=0.003), with 402His/His or 402His/Try genotypes being over-represented among patients compared with controls (13.6% versus 9.4%, P<0.004). A multivariate regression analysis showed that a significantly increased risk of lung cancer for the 402His/His or 402His/Try carriers with OR (95% CI), 1.50 (1.12-2.00). When stratified by smoking status, the elevated risk of the cancer associated with variant CFH genotypes was observed among smokers, but not among non-smokers. When analyzed with cumulative smoking dose (pack-years), a super-multiplicative interaction was observed at different smoking levels. Among carriers with the 402Tyr/His or His/His genotype, the ORs of developing lung cancer for smoking<16, 16-28, or >28 pack-years were 0.98 (0.49-1.94), 2.36 (1.14-4.90), and 6.39 (3.49-11.68), respectively. These findings suggest that CFH Y402H polymorphism may interact with cigarette smoking to effect the development of lung cancer in the Chinese population.
补体系统是对抗肿瘤的重要免疫监视机制,补体因子 H(CFH)是激活补体系统的关键调节剂。已经在几种恶性肿瘤的细胞系中证明了补体因子 H 的表达。在这项研究中,我们研究了 CFH 基因中的单核苷酸多态性(SNP)Try402His(Y402H)(rs1061170)在一项病例对照研究中对肺癌风险的贡献,该研究包括 1000 例病例和 1000 例对照。通过逻辑回归计算比值比(OR)和 95%置信区间(CI)。病例组 CFH Y402H 基因型的频率与对照组有统计学显著差异(χ(2)=8.66,P=0.003),与对照组相比,患者中 402His/His 或 402His/Try 基因型的频率较高(13.6%比 9.4%,P<0.004)。多元回归分析显示,携带 402His/His 或 402His/Try 基因型的肺癌患者患肺癌的风险显著增加,OR(95%CI)为 1.50(1.12-2.00)。按吸烟状态分层时,在吸烟者中观察到与变体 CFH 基因型相关的癌症风险升高,但在非吸烟者中未观察到。当按累积吸烟剂量(包年)分析时,在不同吸烟水平下观察到超倍乘积相互作用。在携带 402Tyr/His 或 His/His 基因型的携带者中,吸烟<16、16-28 或>28 包年的肺癌发生风险的 OR 分别为 0.98(0.49-1.94)、2.36(1.14-4.90)和 6.39(3.49-11.68)。这些发现表明,CFH Y402H 多态性可能与吸烟相互作用,影响中国人群肺癌的发生。